Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Bloom Burton analyst David Martin PhD downgraded Aurinia Pharmaceuticals to a Hold yesterday and set a price target of $13.00. According to TipRank...

Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold

In a report released today, Douglas Miehm from RBC Capital downgraded Aurinia Pharmaceuticals to a Hold, with a price target of $15.00. The company...

Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance

An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third qu...

Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals announced it will report its financial results for the three and ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUPH	$15.68	+3.57%	1.79M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUPH	$15.68	+3.6%	1.79M
3
4
5
6

AUPH

AUPH

Get Aurinia Pharmaceuticals Inc Data in Excel

Get Aurinia Pharmaceuticals Inc Data in Excel